Homozygous familial hypercholesterolemia (HoFH) medications comprise mipomersen and lomitapide. Lomitapide is an FDA-approved in addition to a diet low in fats, and other drugs used to reduce lipids, to decrease low-density lipoprotein (LDL) cholesterol, apolipoprotein B, and other lipoproteins, in patients suffering from HoFH.

**Objectives:**
- Outline the mechanism of action of lomitapide.
- Review the potential side effects of lomitapide.
- Identify the needed monitoring of lomitapide.
- Summerize the plans of the interprofessional team to enhance communication and coordinating care to improve lomitapide and promote outcomes.